Yahoo Finance

Edwards Lifesciences (EW) announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary Resilia tissue technology have significantly improved long-term outcomes compared to those receiving non-Resilia tissue bioprosthetic valves. Presented at the Heart Valve Society Annual Meeting, the study of 947 patients marks the first long-term, propensity-matched comparison between Resilia tissue and non-Resilia tissue surgical aortic valves. The Resilia tissue data from the trial reported encouraging results through eight years, with low rates of structural valve deterioration and freedom from reoperation due to SVD. “These data further validate the growing body of scientific evidence supporting the long-term durability, performance and significant patient benefits of our proprietary RESILIA tissue,” said Wayne Markowitz, Edwards’ senior vice president, surgical structural heart.

Stay Ahead of the Market:

• Discover outperforming stocks and invest smarter with Top Smart Score Stocks.

• Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on EW:

Disclaimer & DisclosureReport an Issue

• Hold Rating Maintained for Edwards Lifesciences Amidst Positive Developments in Mitral Valve Approval and TAVR Challenges

• Balanced Outlook on Edwards Lifesciences Amid TMTT Growth and TAVR Market Challenges

• Edwards Lifesciences receives CE Mark for Sapien M3

• Edwards Lifesciences price target lowered to $75 from $78 at Truist

• Edwards Lifesciences Hold Rating: Balancing Modest Gains and Market Uncertainty